CWM
BMRN icon

Cabot Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cabot Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-11,808
Closed -$978K – 140
2016
Q4 		$978K Sell
11,808
-2,553
-18% -$220K 0.26% 85
2016
Q3 		$1.33M Sell
14,361
-719
-5% -$67.7K 0.34% 85
2016
Q2 		$1.17M Sell
15,080
-232
-2% -$19.7K 0.31% 84
2016
Q1 		$1.26M Sell
15,312
-22,247
-59% -$1.81M 0.35% 75
2015
Q4 		$3.94M Buy
37,559
+15,413
+70% +$1.61M 1.01% 39
2015
Q3 		$2.33M Sell
22,146
-329
-1% -$43.9K 0.64% 63
2015
Q2 		$3.07M Sell
22,475
-137
-0.6% -$17K 0.75% 56
2015
Q1 		$2.82M Sell
22,612
-164
-0.7% -$17.4K 0.69% 56
2014
Q4 		$2.06M Sell
22,776
-26,773
-54% -$2.23M 0.51% 77
2014
Q3 		$3.58M Sell
49,549
-779
-2% -$51.2K 0.91% 46
2014
Q2 		$3.13M Buy
50,328
+1,119
+2% +$67.6K 0.79% 61
2014
Q1 		$3.36M Sell
49,209
-162
-0.3% -$11.9K 0.88% 50
2013
Q4 		$3.47M Sell
49,371
-62
-0.1% -$4.21K 0.91% 47
2013
Q3 		$3.57M Buy
49,433
+16,640
+51% +$1.11M 1.07% 29
2013
Q2 		$1.83M Buy
+32,793
New +$2.04M 0.63% 67

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cabot Wealth Management's BMRN Position: Q1 2017 in Review

Cabot Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2017, closing a stake of 11,808 shares — an estimated $978K sold.

Cabot Wealth Management first reported a position in BMRN in Q2 2013 and held it in 15 quarters. The position peaked at $3.94M in Q4 2015. 418 funds tracked by Wall St. Rank hold BMRN as of Q1 2017.

  • Cabot Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Cabot Wealth Management sold 11,808 BioMarin Pharmaceuticals shares in Q1 2017, an estimated $978K.
  • Cabot Wealth Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 15 quarters.
  • Cabot Wealth Management's BioMarin Pharmaceuticals position peaked at $3.94M in Q4 2015.
  • 418 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2017.

Based on Cabot Wealth Management's 13F filing for Q1 2017, filed 9 May 2017.